EVE Health Group Limited · ASX:EVE

EVE Health — Investor Presentation (November 2026)

18 slides from EVE Health's investor presentation, Nov 12, 2026

  1. Slide 1: EVE Health Group Investor Webinar Business Update

    al use only EVE Health Group Limited We Make Generic Drugs Better. THURSDAY, 12 NOVEMBER 2026 INVESTOR WEBINAR BUSINESS UPDATE ASX: EVE

  2. Slide 2: Who We Are

    WHO WE ARE WHAT WE DO HOW WE DO IT WHY INVEST Who We Are Dedicated to improving generic drugs for patients. ◉ ✦ al use only The Company Why Reformulate? Our Skill Set An ASX-listed Australian life sciences EVE targets established medicines Patent-pending nano-emulsion company building a commercial-

  3. Slide 3: The Erectile Dysfunction Market Opportunity

    WHO WE ARE WHAT WE DO HOW WE DO IT WHY INVEST The Erectile Dysfunction Market Opportunity A large, growing market with high discontinuation and no established fast-onset oral alternative. 322m USD 5.7B ~50% ~61% al use only Men globally affected by ED Global ED treatment market Patients discontinue

  4. Slide 4: Current Treatment Failures

    WHO WE ARE WHAT WE DO HOW WE DO IT WHY INVEST Current Treatment Failures Why conventional treatments drive patient discontinuation. Drug Brand / format Generic Typical onset Patient friction Sildenafil Viagra Yes 1 hr+ Food effect / planning burden al use only Tadalafil Cialis Yes 1 hr+ Long duratio

  5. Slide 5: Libbo — The Solution

    WHO WE ARE WHAT WE DO HOW WE DO IT WHY INVEST Libbo — The Solution Vardenafil oral dissolving film: a reformulated medicine built around patient convenience. ◌ What It Is ≈ How It Works al use only Vardenafil ODF: an established active Nano-emulsion solubilisation supports ingredient in a fast-disso

  6. Slide 6: One Platform. Many Compounds.

    WHO WE ARE WHAT WE DO HOW WE DO IT WHY INVEST One Platform. Many Compounds . A repeatable nano-emulsion process for high-value poorly soluble drugs. al use only Insoluble Nano -emulsion Oral Film or Oral Faster Onset, ◉ ▣ ϟ Molecules Solubilisation Spray Delivery Improved Bioavailability A proven co

  7. Slide 7: Validation Infrastructure Already Built

    WHO WE ARE WHAT WE DO HOW WE DO IT WHY INVEST Validation Infrastructure Already Built Ahead of full product registration, the end-to-end pathway is operating today. Telehealth Prescription Pharmacy Home ◎ Patient ◌ ✓ ▣ Consult Delivery al use only Education Fulfilment Platform › Established › Compli

  8. Slide 8: The Optimal Compounding Agreement

    WHO WE ARE WHAT WE DO HOW WE DO IT WHY INVEST The Optimal Compounding Agreement A binding agreement with Optimal Pharmacy Plus Stafford, entering an Australian compounding channel served largely by generic sildenafil / tadalafil blends (EVE assessment). ✦ The science stays with EVE Capital -light. P

  9. Slide 9: The Men's Sexual Health Compounding Range

    WHO WE ARE WHAT WE DO HOW WE DO IT WHY INVEST The Men's Sexual Health Compounding Range Compounded formulations on EVE’s patent-pending nano-emulsion base for ED, PE and both together. ◌ Erectile Dysfunction ϟ Premature Ejaculation ✦ ED / PE Combination al use only Vardenafil ED formulation. PE form

  10. Slide 10: The Patent Cliff

    WHO WE ARE WHAT WE DO HOW WE DO IT WHY INVEST The Patent Cliff High-value medicines losing exclusivity create differentiated reformulation windows. Target medicine Global sales Patent expiry† EVE relevance Apixaban (Eliquis) USD 12.2B 2026 Pre-BE development al use only Rivaroxaban (Xarelto) USD 6.8

  11. Slide 11: Accelerated Pathway

    WHO WE ARE WHAT WE DO HOW WE DO IT WHY INVEST Accelerated Pathway A capital-efficient route to product registration for established medicines. Conventional new-drug development: Phase I → Phase II → Phase III → 10–15 years → hundreds of millions of dollars. al use only VS Identify Apply EVE’s Produc

  12. Slide 12: Multiple Pillars, One Platform

    WHO WE ARE WHAT WE DO HOW WE DO IT WHY INVEST Multiple Pillars, One Platform Libbo anchors the portfolio. One platform drives multiple franchises and future programs. EVE’s portfolio is structured around multiple complementary programs — all running off the same nano-emulsion platform. al use only M

  13. Slide 13: Key Milestones & Catalysts

    WHO WE ARE WHAT WE DO HOW WE DO IT WHY INVEST Key Milestones & Catalysts Near-term value inflection points across the portfolio. Timing Milestone Detail al use only Binding Master Compounding and Profit Share Agreement executed with Optimal Pharmacy Plus Completed Compounding Agreement Signed Staffo

  14. Slide 14: Why Invest in EVE

    WHO WE ARE WHAT WE DO HOW WE DO IT WHY INVEST Why Invest in EVE A product-led platform with multiple paths to value creation. Product in Use ✦ IP Portfolio ◎ Vast Market ◈ Scalable Model al use only ED, men’s health and Capital-light and partner-led, Libbo shows how the platform Patent applications

  15. Slide 15: Corporate Snapshot

    WHO WE ARE WHAT WE DO HOW WE DO IT WHY INVEST Corporate Snapshot Snapshot Ownership ASX Ticker EVE Share Price (10 Nov 2026) A$0.014 15% Shares on Issue 352m 23% al use only Options on Issue 165m (4-6 cent exercise price) Market Capitalisation (10 Nov 2026) A$4.9m 8% Cash (30 Sept 2026) A$0.84m Ente

  16. Slide 16: EVE Health Group

    EVE Health Group al use only Generic medicines, reimagined through patent-pending delivery science. WWW.EVEHEALTHGROUP.COM.AU © EVE HEALTH GROUP 2026 ASX: EVE | 16

  17. Slide 17: Important Notice & Disclaimer

    Important Notice & Disclaimer This presentation (Presentation) has been prepared by EVE Health Group Limited ABN 89 106 523 611 (EVE or the Clinical and regulatory information Company). The information in this Presentation is of a general background nature, is in summary form and does not Clinical d

  18. Slide 18: References

    References Sources supporting the market, clinical and regulatory claims in this presentation. Previous Disclosure Clinical / Market Sources Compounding Channel References • Australian Bureau of Statistics, Estimated Resident Population by age and sex (ERP_Q), 30 June • “Australian Compounding Agree

EVE Health Group — Investor Presentation (November 2026) on 6ix